Interleukin 10: a new therapeutic target in systemic lupus erythematosus?
- 28 February 2001
- journal article
- editorial
- Published by Elsevier in Joint Bone Spine
- Vol. 68 (1) , 4-5
- https://doi.org/10.1016/s1297-319x(00)00222-0
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosusArthritis & Rheumatism, 2000
- Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase familiesArthritis & Rheumatism, 1999
- Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosusArthritis & Rheumatism, 1998
- Synergistic effect betweenIL-10 andbcl-2 genotypes in determining susceptibility to systemic lupus erythematosusArthritis & Rheumatism, 1998
- Dysregulation of interleukin‐10 production in relatives of patients with systemic lupus erythematosusArthritis & Rheumatism, 1997
- Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.The Journal of Experimental Medicine, 1995
- In vivo production of interleukin‐10 by non–t cells in rheumatoid arthritis, sjöugren's syndrome, and systemic lupus erythematosus.Arthritis & Rheumatism, 1994
- Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice.The Journal of Experimental Medicine, 1994